Common use of Disclosure Program Clause in Contracts

Disclosure Program. Amedisys shall maintain its existing Disclosure Program, including its toll-free compliance telephone line to enable individuals to disclose, to the Corporate Compliance Officer or some other person who is not in the disclosing individual’s chain of command, any identified issues or questions associated with Amedisys’ policies, conduct, practices, or procedures with respect to a Federal health care program, believed by the individual to be a potential violation of criminal, civil, or administrative law. Amedisys shall appropriately publicize the existence of the disclosure mechanism (e.g., via periodic e-mails to employees or by posting the information in prominent common areas) to all Covered Persons. The Disclosure Program shall emphasize Amedisys’ nonretribution, nonretaliation policy, and shall include a reporting mechanism for anonymous communications for which appropriate confidentiality shall be maintained. Upon receipt of a disclosure, the Corporate Compliance Officer (or designee) shall gather all relevant information from the disclosing individual. The Corporate Compliance Officer (or designee) shall make a preliminary, good faith inquiry into the allegations set forth in every disclosure to ensure that he or she has obtained all of the information necessary to determine whether a further review should be conducted. For any disclosure that is sufficiently specific so that it reasonably: (1) permits a determination of the appropriateness of the alleged improper practice; and (2) provides an opportunity for taking corrective action, Amedisys shall conduct an internal review of the allegations set forth in such a disclosure and ensure that proper follow-up is conducted. The Compliance Officer (or designee) shall maintain a disclosure log, which shall include a record and summary of each disclosure received (whether anonymous or not), the status of the respective internal reviews, and any corrective action taken in response to the internal reviews. The disclosure log shall be available to OIG, upon request. Amedisys, Inc. and Amedisys Specialized Medical Services, Inc. Corporate Integrity Agreement 13

Disclosure Program. Amedisys shall maintain its existing Amerigroup has established a Disclosure ProgramProgram that includes a mechanism (e.g., including its a toll-free compliance telephone line line) to enable individuals to disclose, to the Corporate Compliance Officer or some other person who is not in the disclosing individual’s chain of command, any identified issues or questions associated with Amedisys’ Amerigroup’s policies, conduct, practices, or procedures with respect to a Federal health care program, program believed by the individual to be a potential violation of criminal, civil, or administrative law. Amedisys Amerigroup shall appropriately publicize the existence of the disclosure mechanism (e.g., via periodic e-mails to employees or by posting the information in prominent common areas) to all Covered Persons). The Disclosure Program shall emphasize Amedisys’ a nonretribution, nonretaliation policy, and shall include a reporting mechanism for anonymous communications for which appropriate confidentiality shall be maintained. Upon receipt of a disclosure, the Corporate Compliance Officer (or designee) shall gather all relevant information from the disclosing individual. The Corporate Compliance Officer (or designee) shall make a preliminary, good faith inquiry into the allegations set forth in every disclosure to ensure that he or she has obtained all of the information necessary to determine whether a further review should be conducted. For any disclosure that is sufficiently specific so that it reasonably: (1) permits a determination of the appropriateness of the alleged improper practice; and (2) provides an opportunity for taking corrective action, Amedisys Amerigroup shall conduct an internal review of the allegations set forth in such a the disclosure and ensure that proper follow-up is conducted. The Corporate Compliance Officer (or designee) shall maintain a disclosure log, which shall include a record and summary of each disclosure received (whether anonymous or not), the status of the respective internal reviews, and any corrective action taken in response to the internal reviews. The disclosure log shall be made available to OIG, OIG upon request. Amedisys, Inc. and Amedisys Specialized Medical Services, Inc. Corporate Integrity Agreement 13.

Disclosure Program. Amedisys HealthSouth shall maintain its existing a Disclosure ProgramProgram that includes a mechanism (e.g., including its a toll-free compliance telephone line line) to enable individuals to disclose, to the Corporate Compliance Officer or some other person who is not in the disclosing individual’s chain of command, any identified issues or questions associated with Amedisys’ HealthSouth’s policies, conduct, practices, or procedures with respect to a Federal health care program, program believed by the individual to be a potential violation of criminal, civil, or administrative law. Amedisys HealthSouth shall appropriately publicize the existence of the disclosure mechanism (e.g., via periodic e-mails to employees or by posting the information in prominent common areas) to all Covered Persons). The Disclosure Program shall emphasize Amedisys’ a nonretribution, nonretaliation policy, and shall include a reporting mechanism for anonymous communications for which appropriate confidentiality shall be maintained. Upon receipt of a disclosure, the Corporate Compliance Officer (or designee) shall gather all relevant information from the disclosing individual. The Corporate Compliance Officer (or designee) shall make a preliminary, good faith inquiry into the allegations set forth in every disclosure relating to a potential violation of Federal health care program requirements to ensure that he or she has obtained all of the information necessary to determine whether a further review should be conducted. For any disclosure that is sufficiently specific so that it reasonably: (1) permits a determination of the appropriateness of the alleged improper practice; and (2) provides an opportunity for taking corrective action, Amedisys HealthSouth shall conduct an internal review of the allegations set forth in such a the disclosure and ensure that proper follow-up is conducted. The Compliance Officer (or designee) shall maintain a disclosure log, which shall include a record and summary of each disclosure received (whether anonymous or not), the status of the respective internal reviews, and any corrective action taken in response to the internal reviews. The disclosure log shall be made available to OIG, OIG upon request. Amedisys, Inc. and Amedisys Specialized Medical Services, Inc. Corporate Integrity Agreement 13.

Disclosure Program. Amedisys Txxxx has established, and shall maintain its existing for the term of the CIA, a Disclosure ProgramProgram that includes a mechanism (e.g., including its a toll-free compliance telephone line line) to enable individuals to disclose, to the Corporate Compliance Officer or some other person who is not in the disclosing individual’s chain of command, any identified issues or questions associated with Amedisys’ Txxxx’x policies, conduct, practices, or procedures with respect to a Federal health care program, program believed by the individual to be a potential violation of criminal, civil, or administrative law. Amedisys Txxxx shall appropriately publicize the existence of the disclosure mechanism (e.g., via periodic e-mails to employees or by posting the information in prominent common areas) to all Covered Persons). The Disclosure Program shall emphasize Amedisys’ a nonretribution, nonretaliation policy, and shall include a reporting mechanism for anonymous communications for which appropriate confidentiality shall be maintained. Upon receipt of a disclosure, the Corporate Chief Compliance Officer (or designee) shall gather all relevant information from the disclosing individual. The Corporate Chief Compliance Officer (or designee) shall make a preliminary, good faith inquiry into the allegations set forth in every disclosure to ensure that he or she has obtained all of the information necessary to determine whether a further review should be conducted. For any disclosure that is sufficiently specific so that it reasonably: (1) permits a determination of the appropriateness of the alleged improper practice; and (2) provides an opportunity for taking corrective action, Amedisys Txxxx shall conduct an internal review of the allegations set forth in such a the disclosure and ensure that proper follow-up is conducted. The Chief Compliance Officer (or designee) shall maintain a disclosure log, which shall include a record and summary of each disclosure received (whether anonymous or not), the status of the respective internal reviews, and any corrective action taken in response to the internal reviews. The disclosure log shall be made available to OIG, OIG upon request. Amedisys, Inc. and Amedisys Specialized Medical Services, Inc. Corporate Integrity Agreement 13.

Disclosure Program. Amedisys Prior to the Effective Date, Odyssey established and shall continue to maintain its existing a Disclosure ProgramProgram that includes a mechanism (e.g., including its a toll-free compliance telephone line line) to enable individuals to disclose, to the Corporate Compliance Officer or some other person who is not in the disclosing individual’s chain of command, command any identified issues or questions associated with Amedisys’ Odyssey’s policies, conduct, practices, or procedures with respect to a Federal health care program, program believed by the individual to be a potential violation of criminal, civil, or administrative law. Amedisys Odyssey has and shall continue to appropriately publicize the existence of the disclosure mechanism (e.g., via periodic e-mails to employees or by posting the information in prominent common areas) to all Covered Persons). The Disclosure Program shall emphasize Amedisys’ a nonretribution, nonretaliation policy, and shall include a reporting mechanism for anonymous communications for which appropriate confidentiality shall be maintained. Upon receipt of a disclosure, the Corporate Compliance Officer (or designee) shall gather all relevant information from the disclosing individual. The Corporate Compliance Officer (or designee) shall make a preliminary, good faith inquiry into the allegations set forth in every disclosure to ensure that he or she has obtained all of the information necessary to determine whether a further review should be conducted. For any disclosure that is sufficiently specific so that it reasonably: (1) permits a determination of the appropriateness of the alleged improper practice; and (2) provides an opportunity for taking corrective action, Amedisys Odyssey shall conduct an internal review of the allegations set forth in such a the disclosure and ensure that proper follow-up is conducted. Odyssey Corporate Integrity Agreement The Compliance Officer (or designee) shall maintain a disclosure log, which shall include a record and summary of each disclosure received (whether anonymous or not), the status of the respective internal reviews, and any corrective action taken in response to the internal reviews. The disclosure log shall be made available to OIG, OIG upon request. Amedisys, Inc. and Amedisys Specialized Medical Services, Inc. Corporate Integrity Agreement 13.

Disclosure Program. Amedisys Within 90 days after the Effective Date, All Smiles shall maintain its existing establish a Disclosure ProgramProgram that includes a mechanism (e.g., including its a toll-free compliance telephone line line) to enable individuals to disclose, to the Corporate Compliance Officer or some other person who is not in the disclosing individual’s chain of command, any identified issues or questions associated with AmedisysAll Smiles’ policies, conduct, practices, or procedures with respect to a Federal health care program, program believed by the individual to be a potential violation of criminal, civil, or administrative law. Amedisys All Smiles shall appropriately publicize the existence of the disclosure mechanism (e.g., via periodic e-mails to employees or by posting the information in prominent common areas) to all Covered Persons). The Disclosure Program shall emphasize Amedisys’ a nonretribution, nonretaliation policy, and shall include a reporting mechanism for anonymous communications for which appropriate confidentiality shall be maintained. Upon receipt of a disclosure, the Corporate Compliance Officer (or designee) shall gather all relevant information from the disclosing individual. The Corporate Compliance Officer (or designee) shall make a preliminary, good faith inquiry into the allegations set forth in every disclosure to ensure that he or she has obtained all of the information necessary to determine whether a further review should be conducted. For any disclosure that is sufficiently specific so that it reasonably: (1) permits a determination of the appropriateness of the alleged improper practice; and (2) provides an opportunity for taking corrective action, Amedisys All Smiles shall conduct an internal review of the allegations set forth in such a the disclosure and ensure that proper follow-up is conducted. The Compliance Officer (or designee) shall maintain a disclosure log, which shall include a record and summary of each disclosure received (whether anonymous or not), the status of the respective internal reviews, and any corrective action taken in response to the internal reviews. The disclosure log shall be available to OIG, upon request. Amedisys, Inc. and Amedisys Specialized Medical Services, Inc. Corporate Integrity Agreement 13.

Disclosure Program. Amedisys Within 90 days after the Effective Date, Maximus shall maintain its existing establish a Disclosure ProgramProgram that includes a mechanism (e.g., including its a toll-free compliance telephone line line) to enable individuals to disclose, to the Corporate Compliance Officer or some other person who is not in the disclosing individual’s chain of command, any identified issues or questions associated with AmedisysMaximus’ policies, conduct, practices, or procedures with respect to a Federal health care program, program believed by the individual to be a potential violation of criminal, civil, or administrative law. Amedisys Maximus shall appropriately publicize the existence of the disclosure mechanism (e.g., via periodic e-mails to employees or by posting the information in prominent common areas) to all Covered Persons). The Disclosure Program shall emphasize Amedisys’ a nonretribution, nonretaliation policy, and shall include a reporting mechanism for anonymous communications for which appropriate confidentiality shall be maintained. Upon receipt of a disclosure, the Corporate Compliance Officer (or designee) shall gather all relevant information from the disclosing individual. The Corporate Compliance Officer (or designee) shall make a preliminary, good faith inquiry into the allegations set forth in every disclosure to ensure that he or she has obtained all of the information necessary to determine whether a further review should be conducted. For any disclosure that is sufficiently specific so that it reasonably: (1) permits a determination of the appropriateness of the alleged improper practice; and (2) provides an opportunity for taking corrective action, Amedisys Maximus shall conduct an internal review of the allegations set forth in such a the disclosure and ensure that proper follow-up is conducted. The Compliance Officer (or designee) shall maintain a disclosure log, which shall include a record and summary of each disclosure received (whether anonymous or not), the status of the respective internal reviews, and any corrective action taken in response to the internal reviews. The disclosure log shall be made available to OIG, OIG upon request. Amedisys, Inc. and Amedisys Specialized Medical Services, Inc. Corporate Integrity Agreement 13.

Disclosure Program. Amedisys Within 90 days after the Effective Date, Maximus shall maintain its existing establish a Disclosure ProgramProgram that includes a mechanism (e.g., including its a toll-free compliance telephone line line) to enable individuals to disclose, to the Corporate Compliance Officer Officer or some other person who is not in the disclosing individual’s chain of command, any identified identified issues or questions associated with AmedisysMaximus’ policies, conduct, practices, or procedures with respect to a Federal health care program, program believed by the individual to be a potential violation of criminal, civil, or administrative law. Amedisys Maximus shall appropriately publicize the existence of the disclosure mechanism (e.g., via periodic e-mails to employees or by posting the information in prominent common areas) to all Covered Persons). The Disclosure Program shall emphasize Amedisys’ a nonretribution, nonretaliation policy, and shall include a reporting mechanism for anonymous communications for which appropriate confidentiality confidentiality shall be maintained. Upon receipt of a disclosure, the Corporate Compliance Officer Officer (or designee) shall gather all relevant information from the disclosing individual. The Corporate Compliance Officer Officer (or designee) shall make a preliminary, good faith inquiry into the allegations set forth in every disclosure to ensure that he or she has obtained all of the information necessary to determine whether a further review should be conducted. For any disclosure that is sufficiently specific sufficiently specific so that it reasonably: (1) permits a determination of the appropriateness of the alleged improper practice; and (2) provides an opportunity for taking corrective action, Amedisys Maximus shall conduct an internal review of the allegations set forth in such a the disclosure and ensure that proper follow-up is conducted. The Compliance Officer Officer (or designee) shall maintain a disclosure log, which shall include a record and summary of each disclosure received (whether anonymous or not), the status of the respective internal reviews, and any corrective action taken in response to the internal reviews. The disclosure log shall be made available to OIG, OIG upon request. Amedisys, Inc. and Amedisys Specialized Medical Services, Inc. Corporate Integrity Agreement 13.

Disclosure Program. Amedisys Rotech shall continue to maintain its existing a Disclosure ProgramProgram that includes a mechanism (e.g., including its a toll-free compliance telephone line line) to enable individuals to disclose, to the Corporate Compliance Officer or some other person who is not in the disclosing individual’s chain of command, any identified issues or questions associated with Amedisys’ Rotech’s policies, conduct, practices, or procedures with respect to a Federal health care program, program believed by the individual to be a potential violation of criminal, civil, or administrative law. Amedisys Rotech shall appropriately publicize the existence of the disclosure mechanism (e.g., via periodic e-mails to employees or by posting the information in prominent common areas) to all Covered Persons). Rotech Healthcare Inc. Corporate Integrity Agreement The Disclosure Program shall emphasize Amedisys’ a nonretribution, nonretaliation policy, and shall include a reporting mechanism for anonymous communications for which appropriate confidentiality shall be maintained. Upon receipt of a disclosure, the Corporate Compliance Officer (or designee) shall gather all relevant information from the disclosing individual. The Corporate Compliance Officer (or designee) shall make a preliminary, good faith inquiry into the allegations set forth in every disclosure to ensure that he or she has obtained all of the information necessary to determine whether a further review should be conducted. For any disclosure that is sufficiently specific so that it reasonably: (1) permits a determination of the appropriateness of the alleged improper practice; and (2) provides an opportunity for taking corrective action, Amedisys Rotech shall conduct an internal review of the allegations set forth in such a the disclosure and ensure that proper follow-up is conducted. The Compliance Officer (or designee) shall maintain a disclosure log, which shall include a record and summary of each disclosure received (whether anonymous or not), the status of the respective internal reviews, and any corrective action taken in response to the internal reviews. The disclosure log shall be made available to OIG, OIG upon request. Amedisys, Inc. and Amedisys Specialized Medical Services, Inc. Corporate Integrity Agreement 13.

Disclosure Program. Amedisys Maxim has established and shall maintain its existing a Disclosure ProgramProgram that includes a mechanism (e.g., including its a toll-free compliance telephone line line) to enable individuals to disclose, to the Corporate Compliance Officer or some other person who is not in the disclosing individual’s chain of command, any identified issues or questions associated with Amedisys’ Maxim’s policies, conduct, practices, or procedures with respect to a Federal health care program, program believed by the individual to be a potential violation of criminal, civil, or administrative law. Amedisys Maxim shall appropriately publicize the existence of the disclosure mechanism (e.g., via periodic e-mails to employees or by posting the information in prominent common areas) to all Covered Persons). The Disclosure Program shall emphasize Amedisys’ nonretributiona non-retribution, nonretaliation non-retaliation policy, and shall include a reporting mechanism for anonymous communications for which appropriate confidentiality shall be maintained. Upon receipt of a disclosure, the Corporate Compliance Officer (or designee) shall gather all relevant information from the disclosing individual. The Corporate Compliance Officer (or designee) shall make a preliminary, good faith inquiry into the allegations set forth in every disclosure to ensure that he or she has obtained all of the information necessary to determine whether a further review should be conducted. For any disclosure that is sufficiently specific so that it reasonably: (1) permits a determination of the appropriateness of the alleged improper practice; and (2) provides an opportunity for taking corrective action, Amedisys Maxim shall conduct an internal review of the allegations set forth in such a the disclosure and ensure that proper follow-up is conducted. The Compliance Officer (or designee) shall maintain a disclosure log, which shall include a record and summary of each disclosure received (whether anonymous or not), the status of the respective internal reviews, and any corrective action taken in response to the internal reviews. The disclosure log shall be made available to OIG, OIG upon request. Amedisys, Inc. and Amedisys Specialized Medical Services, Inc. Corporate Integrity Agreement 13.